CRMD CorMedix Inc.

CorMedix Inc. To Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 9, 2024

CorMedix Inc. To Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 9, 2024

BERKELEY HEIGHTS, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the first quarter ended March 31, 2024, before the market opens on Thursday, May 9, 2024, and will host a corporate update conference call at 8:30am Eastern Time.

Thursday, May 9th @ 8:30am ET
Domestic:1-888-886-7786
International:1-416-764-8658
Conference ID:32817785
Webcast:
  

About CorMedix

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath®, which was approved by the FDA on November 15, 2023 and launched in inpatient settings in April 2024. CorMedix anticipates the commercial launch of DefenCath in outpatient settings in July 2024. CorMedix also intends to develop DefenCath as a catheter lock solution for use in other patient populations. For more information visit: .

Investor Contact:

Dan Ferry

Managing Director

LifeSci Advisors



(617) 430-7576



EN
06/05/2024

Underlying

CRMDCorMedix Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CorMedix Inc.

 PRESS RELEASE
Free
CRMD CORMEDIX INC.

CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Resu...

CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update ‒ Q4 2025 Net Revenue of $128.6 million ‒ ‒ Pro Forma Full Year 2025 Net Revenue of $401.3 million ‒   ‒ Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ PARSIPPANY, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial...

March 5, 2026 1 EN
 PRESS RELEASE
Free
CRMD CORMEDIX INC.

CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Re...

CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026 BERKELEY HEIGHTS, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025, before the market opens on Thursday, March 5, 2026, and will host a corporate update conference call at 8:30am Easter...

March 2, 2026 1 EN
 PRESS RELEASE
Free
CRMD CORMEDIX INC.

CorMedix to Participate in Upcoming Investor Conferences

CorMedix to Participate in Upcoming Investor Conferences BERKELEY HEIGHTS, N.J., Feb. 12, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be presenting and participating in investor meetings at upcoming investor conferences taking place in March. Leerink Partners Global Healthcare ConferenceDate: March 10, 2026Time: 1:00pm EasternFormat: Fireside ChatWebcast:    Citizens Life Sciences ConferenceD...

February 12, 2026 1 EN
 PRESS RELEASE
Free
CRMD CORMEDIX INC.

CorMedix Therapeutics Announces Share Repurchase Program

CorMedix Therapeutics Announces Share Repurchase Program BERKELEY HEIGHTS, N.J., Feb. 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced its Board of Directors has approved a share repurchase program, which authorizes the Company to repurchase up to $75 million of the Company’s outstanding common stock. The repurchase program is authorized through December 31, 2027. “With a strong balance sheet, solid operating performanc...

February 2, 2026 1 EN
 PRESS RELEASE
Free
CRMD CORMEDIX INC.

CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New...

CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026 BERKELEY HEIGHTS, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will host an in-person and virtual analyst day in New York on Tuesday, February 10, 2026 with presentations and panels from 1:00 PM to 3:00 PM Eastern. The Company will share background and updates across its portfolio and pipeline, and outl...

January 29, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch